Remarkable Lorundrostat Trial Noted by JAMA Research Roundup
Lorundrostat cut automated office systolic blood pressure by a mean 16.9 mmHg at Week 6 and 19.0 mmHg at...
eClinical Tech News
FDA Approves Uplizna, A New Hope for Myasthenia Gravis
FDA has approved inebilizumab-cdon (Uplizna) for generalized myasthenia gravis in adults who are anti-AChR and anti-MuSK antibody positive, based...
Tenaya’s Heart Gene Therapy Shows Promising Early Results
At the 3E13 vg/kg dose in Tenaya Therapeutics’ RIDGE-1 Phase 1b/2 study, three adults with PKP2-associated ARVC showed early...
First Patient Dosed in Tiziana’s Phase 2 Alzheimer’s Trial
TSPO-PET imaging in an Alzheimer’s patient already on lecanemab showed persistent, widespread microglial activation, underscoring residual neuroinflammation despite amyloid...
Parexel’s Spectacular Win: Named Best CRO at Scrip Awards
Parexel has been named Best Contract Research Organization in the full-service category at the 21st Scrip Awards, a peer-judged...
TissueCypher: A Breakthrough in Esophageal Cancer Risk ID
Across six published studies, patients flagged as high risk by Castle Biosciences’ TissueCypher Barrett’s Esophagus test were 6.7 times...
FDA Approves ORLADEYO, First Oral HAE Drug for Children
Interim data from APeX-P, the largest pediatric HAE prophylaxis study to date in patients aged 2 to under 12,...
Novabridge Reveals Promising Ragistomig Phase 1 Data at ESMO
In a Phase 1 expansion of ragistomig, a 4-1BB × PD-L1 bispecific, the 3 mg/kg every-six-weeks regimen delivered an...
Promising Results for Samuraciclib in Advanced Breast Cancer
Samuraciclib plus fulvestrant delivered an overall response rate of 55% and a median progression-free survival of 14.5 months in...
Barinthus Bio Phase 1 Avalon Celiac Trial Update
In the single-ascending dose portion of the first-in-human AVALON trial (NCT06310291), VTP-1000 was well tolerated with no treatment-related serious...